Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erwinaze PK Study in Adult AML
NCT02283190Phase 1Completed
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Asparaginase erwinia chrysanthemi in acute myeloid leukemia (AML). Primary endpoints: Recommended Phase 2 Dose at Day 3 and Plasma Glutamine Level at Day 42. Started Apr 2014; status: completed.
02
Drugs
Asparaginase erwinia chrysanthemi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02283190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283190.